The company was founded in 1897 and is based in midwestern US. The firm is a family-owned company active in several areas of the healthcare industry, and is interested in forming strategic relationships with companies working in its core fields. The structure of these relationships varies, but generally involves in-licensing and co-promotion. The firm prefers to form relationships with companies that are (or very soon will be) at the commercial stage and are seeking a partner that can provide a distribution channel and support rapid growth.

The firm’s current primary interest is in medical devices that address infection prevention, particularly prevention of hospital-acquired infections; the group is also interested in partnering with companies developing diagnostic devices that are used in a critical care or ICU setting, and products for gastrointestinal and anal-rectal health. While the firm generally forms partnerships involving devices that have received FDA approval, the group may also be interested in devices that are not yet approved but have strong clinical evidence that shows a significant advantage over the current standard of care. Additionally, the firm is interested in non-prescription medical products that address age management for women (including aesthetics and menopause), and non-prescription topical products.

The firm is primarily focused on forming relationships with companies in the US market. As the company uses a launchpad strategy that involves deploying a nationwide salesforce to create fast market uptake for a partner’s product with the goal of growing the value and market share of their partner’s assets prior to attaining an exit, the firm invests in opportunities that can achieve an exit in 2-3 years.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a corporate venture firm founded in 2020 and headquartered in Colorado. The firm has a team of three investors and growing, with five active portfolio companies and one exit. The firms typical check size ranges from $1-10M in Seed stage and beyond, with Series A being their sweet spot. Because of the flexibility in their balance sheet and investment committee, the firm has also looked at investments greater than $10M in Series C and D companies. The firm typically makes equity investments but has used notes for later stage investments. The firm is USA focused however the firm will look at companies headquartered elsewhere if there’s USA commercial traction or intent to commercialize in the US.

The firm is interested in diagnostic and digital health sectors and is open to all subsectors and indications. The firm is not interested in therapeutics or medical devices, unless they’re noninvasive medical devices. The firm is especially interested in technology that impacts their polychronic patients, especially since the firm has a strong intention of moving upstream into the CKD and ESKD

space. The firm has done a lot of work in the cardiometabolic and comorbidity space, more specifically looking at technology for cardiovascular disease, diabetes, COPD, social determinants of health, end of life and behavioral health.

The firm is open to all types of management teams but have a preference for entrepreneurial experience, however the firm has also backed first time founders. For companies not in the diagnostics or device space, the firm likes to see at least $1M in ARR. They firm has led in the past but prefers to join syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm founded in 2020 and is headquartered in Paris, France, with an additional office based in the USA. The firm is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A corporate venture firm founded in 2020 is headquartered in Denver, Colorado. The firm’s typical check size ranges from $1-10M in Seed stage and beyond, with Series A being their sweet spot. Because of the flexibility in their balance sheet and investment committee, the firm has also looked at investments greater than $10M in Series C and D companies. The firm typically makes equity investments but has used notes for later stage investments. The firm is USA focused but will look at companies headquartered elsewhere if there’s USA commercial traction or intent to commercialize in the US.

The firm is interested in diagnostic and digital health sectors and is open to all subsectors and indications. The firm is not interested in therapeutics or medical devices, unless they’re noninvasive medical devices. The firm is especially interested in technology that impacts their polychronic patients, especially since the firm has a strong intention of moving upstream into the CKD and ESKD space. The firm has done a lot of work in the cardiometabolic and comorbidity space, more specifically looking at technology for cardiovascular disease, diabetes, COPD, social determinants of health, end of life and behavioral health.

The firm prefers management teams with entrepreneurial experience but is open to all types of management teams and has backed first-time founders. For companies not in the diagnostics or device space, The firm likes to see at least $1M in ARR. The firm has led in the past but prefers to join syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.